Medicalsystem Biotechnology Co., Ltd (SHE:300439)
China · Delayed Price · Currency is CNY 8.70
-0.21 (-2.36%)
Jun 8, 2026, 3:04 PM CST
SHE:300439 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,517 | 1,515 | 1,728 | 1,875 | 2,473 | 2,238 |
Other Revenue | 23.85 | 23.85 | 14.7 | 11.01 | 16.37 | 13.6 |
| 1,541 | 1,539 | 1,742 | 1,886 | 2,489 | 2,252 | |
Revenue Growth (YoY) | -5.74% | -11.67% | -7.61% | -24.23% | 10.55% | -2.19% |
Cost of Revenue | 999.31 | 993.22 | 972.72 | 1,060 | 1,552 | 1,348 |
Gross Profit | 541.84 | 545.94 | 769.7 | 825.44 | 937.49 | 903.98 |
Selling, General & Admin | 399.42 | 398.7 | 403.11 | 440.58 | 475.15 | 475.35 |
Research & Development | 120.21 | 127.2 | 146.47 | 149.8 | 171.78 | 150.68 |
Other Operating Expenses | 8.92 | 9.24 | -0.78 | 8.36 | 12.94 | 17.5 |
Operating Expenses | 535.67 | 540.43 | 529.07 | 594.47 | 700.85 | 665.38 |
Operating Income | 6.18 | 5.51 | 240.63 | 230.97 | 236.63 | 238.6 |
Interest Expense | -2.34 | -2.57 | -2.52 | -10.66 | -15.63 | -29.26 |
Interest & Investment Income | 12.71 | 12.6 | 24.81 | 28.2 | 11.18 | 6.69 |
Currency Exchange Gain (Loss) | -0.31 | -0.31 | -2.56 | -0.64 | 4.34 | -2.9 |
Other Non Operating Income (Expenses) | -1.14 | -1.73 | 0.85 | 27.01 | -13.24 | -3.67 |
EBT Excluding Unusual Items | 15.09 | 13.51 | 261.21 | 274.87 | 223.27 | 209.46 |
Impairment of Goodwill | - | - | - | - | - | -3.89 |
Gain (Loss) on Sale of Investments | -9.14 | -12.03 | -11.11 | -3.6 | -9.69 | -15.98 |
Gain (Loss) on Sale of Assets | 1.65 | 1.66 | -0.67 | -0.78 | -0.32 | 0.48 |
Asset Writedown | -0.21 | -0.3 | -2.2 | -10.87 | -13.1 | -0.13 |
Other Unusual Items | 42.61 | 43.25 | 35.13 | 36.06 | 23.15 | 28.3 |
Pretax Income | 50.01 | 46.09 | 282.36 | 295.68 | 223.31 | 218.24 |
Income Tax Expense | -14.77 | -15.27 | 19.69 | 36.18 | 18.1 | 28.08 |
Earnings From Continuing Operations | 64.77 | 61.36 | 262.67 | 259.5 | 205.2 | 190.15 |
Minority Interest in Earnings | 1.8 | 1.84 | -4.68 | -2.95 | -6.68 | -10.66 |
Net Income | 66.57 | 63.2 | 258 | 256.55 | 198.53 | 179.49 |
Net Income to Common | 66.57 | 63.2 | 258 | 256.55 | 198.53 | 179.49 |
Net Income Growth | -68.19% | -75.50% | 0.56% | 29.23% | 10.61% | -40.07% |
Shares Outstanding (Basic) | 394 | 395 | 385 | 383 | 382 | 374 |
Shares Outstanding (Diluted) | 394 | 395 | 385 | 383 | 382 | 374 |
Shares Change (YoY) | 2.05% | 2.58% | 0.56% | 0.30% | 2.10% | 8.59% |
EPS (Basic) | 0.17 | 0.16 | 0.67 | 0.67 | 0.52 | 0.48 |
EPS (Diluted) | 0.17 | 0.16 | 0.67 | 0.67 | 0.52 | 0.48 |
EPS Growth | -68.83% | -76.12% | - | 28.85% | 8.33% | -44.81% |
Free Cash Flow | 89.13 | 75.21 | -22.73 | 353.16 | 261.53 | 313.67 |
Free Cash Flow Per Share | 0.23 | 0.19 | -0.06 | 0.92 | 0.69 | 0.84 |
Dividend Per Share | 0.033 | 0.033 | 0.135 | 0.134 | 0.105 | 0.095 |
Dividend Growth | -75.56% | -75.56% | 0.75% | 27.62% | 10.53% | -39.38% |
Gross Margin | 35.16% | 35.47% | 44.17% | 43.77% | 37.66% | 40.15% |
Operating Margin | 0.40% | 0.36% | 13.81% | 12.25% | 9.51% | 10.60% |
Profit Margin | 4.32% | 4.11% | 14.81% | 13.60% | 7.98% | 7.97% |
Free Cash Flow Margin | 5.78% | 4.89% | -1.30% | 18.73% | 10.51% | 13.93% |
EBITDA | 143.06 | 153.86 | 434.82 | 383.73 | 406.75 | 412.01 |
EBITDA Margin | 9.28% | 10.00% | 24.95% | 20.35% | 16.34% | 18.30% |
D&A For EBITDA | 136.88 | 148.34 | 194.19 | 152.76 | 170.12 | 173.4 |
EBIT | 6.18 | 5.51 | 240.63 | 230.97 | 236.63 | 238.6 |
EBIT Margin | 0.40% | 0.36% | 13.81% | 12.25% | 9.51% | 10.60% |
Effective Tax Rate | - | - | 6.97% | 12.24% | 8.11% | 12.87% |
Revenue as Reported | 1,541 | 1,539 | 1,742 | 1,886 | 2,489 | 2,252 |